EN DE
Watch Zim Laboratories Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zim Laboratories Limited (ZIMLAB) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Zim Laboratories Limited stock ₹19.02, price ₹140, that is 86.4% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE518E01015

ZL Zim Laboratories Limited logo Thin data Nov 15, 2026

Zim Laboratories Limited

ZIMLAB · NSE

Far too expensive (fair value 86% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Revenue last quarter +31% vs. a year ago. 
Thin margins · 0.9% net margin (TTM) 
Fair value ₹19.02 · Strongly overvalued 
Quality 37/100 
Weak Growth (revenue 3y −2.5 %/yr in INR) 
Negative free cash flow 
Trails peers (2/12) 
Narrow moat 19/100 · thin data
Thin data 
Extreme value
Watch Zim Laboratories Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹152.63 ₹60.26 Fair Value ₹19.02 Nov 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

48‑month range ₹60.26 – ₹152.63 · fair‑value band ₹13.31 – ₹24.72 · the ₹139.87 price screens above the ₹19.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Zim Laboratories in your weekly email

Every Wednesday you see whether Zim Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally.

Show moreShow less

It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films.

The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was founded in 1984 and is based in Nagpur, India.

Stock analysis

Zim Laboratories Limited (ZIMLAB) currently trades at ₹139.87, while our model-based Fair Value estimate is ₹19.02, 86% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ₹36.07 per share, and 1 of the 13 models we run sit above the ₹139.87 price.

Bear case: the Earnings-Based group reads lowest at ₹3.95, and 12 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹13.31 (bear) to ₹24.72 (bull), the price of ₹139.87 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Zim Laboratories Limited reported revenue of ₹3.7B in FY2026 versus ₹3.3B in FY2022, a compound +2.8%/yr. Reported net income was ₹58.4M in FY2026, compounding −20.4%/yr from FY2022.

Key figures

Market cap ₹6.9B (≈ $72.8M) Micro · P/E ratio 170.6 · P/S ratio 1.74 · EPS (TTM) ₹0.8200 · Net margin 0.9% · Return on equity 2.1% · Return on assets (EBIT) 9.1% (5-year average) · Operating margin −3.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 132% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −86%, ZIMLAB screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (₹0.0800 to ₹213.48). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹13.31 Fair Value ₹19.02 Bull ₹24.72
Price ₹139.87 · Downside -86.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹0.5167 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ₹26.90 ₹29.55 ₹32.94 76
EPV ₹0.7300 ₹1.12 ₹1.43 73
ROIC Compounder ₹0.7300 ₹1.12 ₹1.43 71
All 14 models by family
Earnings-Based
Graham-Dodd ₹7.41 ₹16.22 ₹20.67 66
PEG = 1.0 ₹2.76 ₹3.95 ₹5.13 57
EPV ₹0.7300 ₹1.12 ₹1.43 73
Dividend Discount
Gordon GGM ₹0.0600 ₹0.0800 ₹0.1000 69
DDM Multi-Stage ₹0.0600 ₹0.0800 ₹0.1000 67
Multiples
P/E Multiple ₹17.99 ₹23.99 ₹29.98 63
P/S Multiple ₹13.90 ₹18.53 ₹23.17 58
P/B Multiple ₹160.11 ₹213.48 ₹266.85 55
EV/EBIT n/a n/a ₹3.58 61
EV/EBITDA ₹31.37 ₹48.14 ₹64.90 66
Asset-Based
NCAV (Graham) ₹4.01 ₹6.08 ₹7.60 54
Economic Profit
Residual Income ₹26.90 ₹29.55 ₹32.94 76
ROIC Compounder ₹0.7300 ₹1.12 ₹1.43 71
Growth Earnings
Growth-Adj P/E ₹13.31 ₹19.02 ₹24.72 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 14
Are margins and returns getting better?
Cashflow 38
Do the profits arrive as real cash?
Financial strength 56
Debt, balance sheet and risk of trouble
Investment 31
Does it invest with discipline instead of growing at any price?
Low Volatility 51
How calm the share price moves, does not count
Price momentum 92
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 93
Distance to the 52-week high, does not count
New shares 76
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
Start year 2021 (pandemic). Over 10 years: +3.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4.6% vs −6.9%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 2%
Pace: the 5-year rate starts in 2021 (pandemic)

ZIMLAB screens overvalued: fair value 86% below the price. Compare with Merck KGaA →

Compare Zim Laboratories Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −86.5% · Bottom 25%
Profitability
Return on equity (12 months) 2.1% · Below median
Return on assets 1.1% · Below median
Net margin (12 months) 0.9% · Below median
Operating margin (12 months) −3.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 31.2% · Top 25%
Balance sheet
Debt / equity 0.14× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 170.6× · Priciest 25%
P/B 2.33× · Pricier than median
P/S (12 months) 1.74× · Cheaper than median
EV/EBITDA 31.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)9 · sector 26
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs ZIMLAB
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs ZIMLAB
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs ZIMLAB
Haleon plc HLN $9.17 $8.47 −8% vs ZIMLAB
Merck KGaA MRK €149.60 €108.83 −27% vs ZIMLAB
Galderma Group GALD CHF 191.40 CHF 112.30 −41% vs ZIMLAB
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs ZIMLAB
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs ZIMLAB
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs ZIMLAB
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs ZIMLAB

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zim Laboratories Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zim Laboratories Limited Fair Value". https://www.fairvalue-calculator.com/stock/ZIMLAB

Frequently asked questions

Is Zim Laboratories Limited (ZIMLAB) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of ₹19.02 versus a price of ₹139.87, about 86% lower (overvalued).
What is the fair value of ZIMLAB?
Our model-based fair value for Zim Laboratories Limited is ₹19.02 (as of Nov 15, 2026), built from audited fundamentals. The current price: ₹139.87.
What is the quality score of ZIMLAB?
Zim Laboratories Limited has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zim Laboratories Limited (ZIMLAB)?
Our model-based price target is the fair value of ₹19.02 (as of Nov 15, 2026) from 14 valuation models. Cautious scenario ₹13.31, optimistic scenario ₹24.72. It is a calculation from audited fundamentals, not an analyst target.
What is the Zim Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹19.02, about 86% lower versus a price of ₹139.87 (overvalued). Cautious scenario ₹13.31, optimistic scenario ₹24.72. The calculation is refreshed regularly with new filings.
What is the revenue of Zim Laboratories Limited (ZIMLAB)?
Zim Laboratories Limited reported trailing-twelve-month revenue of about ₹4.0B (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Zim Laboratories Limited (ZIMLAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zim Laboratories Limited it is ₹19.02 per share (as of Nov 15, 2026), against a price of ₹139.87. It is the blended result of 14 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Zim Laboratories Limited stock overvalued or undervalued in 2026?
As of Nov 15, 2026, ZIMLAB trades above its calculated fair value: price ₹139.87, fair value ₹19.02, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZIMLAB?
No. The price is what the market pays today (₹139.87); the fair value is what the company's own numbers justify (₹19.02). For Zim Laboratories Limited the two are ₹120.85 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zim Laboratories Limited worth?
The market values Zim Laboratories Limited at about ₹6.9B (market capitalisation, as of Nov 15, 2026). Per share that is ₹139.87; our models calculate a fair value of ₹19.02 per share.
What do the bullish and bearish scenarios say about ZIMLAB?
Our models span a range for Zim Laboratories Limited: cautious scenario ₹13.31, base ₹19.02, optimistic ₹24.72 per share (as of Nov 15, 2026, price ₹139.87). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ZIMLAB?
Zim Laboratories Limited trades at a price-to-earnings ratio of 170.6 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹19.02 is built from several models across several years. Other multiples: P/B 2.3, P/S 1.7, EV/EBITDA 31.6.
How solid is the balance sheet of Zim Laboratories Limited (ZIMLAB)?
Balance-sheet figures for Zim Laboratories Limited (as of Nov 15, 2026): return on equity 2.1%, debt of 0.14 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is ZIMLAB from its 52-week high?
Zim Laboratories Limited trades at ₹139.87, about 8% below its 52-week high of ₹152.63 and 132% above the low of ₹60.26 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹19.02 is for.
Which stocks are comparable to Zim Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zim Laboratories Limited stock attractive at the current price?
The data as of Nov 15, 2026: price ₹139.87, calculated fair value ₹19.02 (−86%), Quality Score 37/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZIMLAB calculated?
We run Zim Laboratories Limited through 14 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹19.02 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Zim Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zim Laboratories Limited (ZIMLAB)?
The closing price on Nov 16, 2026 was ₹139.87. Our model-based fair value is ₹19.02, about 86% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zim Laboratories Limited right now?
The price sits above even our optimistic bull case (₹24.72). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹13.31 to ₹24.72) leaves room in how you read the outcome.
Where does the earnings growth of Zim Laboratories Limited (ZIMLAB) come from?
Earnings per share at Zim Laboratories Limited fell 0.1 % a year from 2016 to 2026. Broken into its drivers: revenue per share +4.8 %, EBIT margin +3.3 %, tax rate −4.4 %, residual (interest, one-offs) −3.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Zim Laboratories Limited

How large is the market capitalisation of Zim Laboratories Limited (ZIMLAB)?
The market capitalisation of Zim Laboratories Limited is ₹6.9B (≈ $72.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zim Laboratories Limited (ZIMLAB)?
The price-to-sales ratio of Zim Laboratories Limited is 1.74 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zim Laboratories Limited (ZIMLAB)?
Earnings per share at Zim Laboratories Limited are ₹0.8200 (price ÷ EPS = P/E 170.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zim Laboratories Limited (ZIMLAB)?
The net margin of Zim Laboratories Limited is 0.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zim Laboratories Limited (ZIMLAB)?
The return on equity (ROE) of Zim Laboratories Limited is 2.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zim Laboratories Limited (ZIMLAB)?
On an EBIT basis the return on assets of Zim Laboratories Limited is 9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zim Laboratories Limited (ZIMLAB)?
The operating margin of Zim Laboratories Limited is −3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zim Laboratories Limited (ZIMLAB)?
Revenue at Zim Laboratories Limited is growing 31.2% versus a year earlier (3y avg −2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zim Laboratories Limited (ZIMLAB)?
Earnings per share at Zim Laboratories Limited are down 24.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zim Laboratories Limited (ZIMLAB) generate?
The free cash flow of Zim Laboratories Limited is −₹75.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zim Laboratories Limited (ZIMLAB) carry?
The net debt of Zim Laboratories Limited is ₹1.0B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Zim Laboratories Limited in the live analysis

One click puts Zim Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.